GSK publishes payments for research, consulting and advising by US healthcare professionals
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (NYSE:GSK) published a list of payments made during 2010 for clinical research studies led by U.S. healthcare professionals.
Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010
- Details
- Category: Pfizer
Pfizer Inc. released a report detailing the company's financial interactions with health care professionals and researchers in 2010.
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment
- Details
- Category: Nycomed
Nycomed announced plans for an international phase III/IV study investigating the effect of Daxas® versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists (LABA) and inhaled corticosteroids (ICS),
Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the registration statement relating to the Contingent Value Rights (CVRs) offered to Genzyme shareholders as part of sanofi-aventis' agreement to acquire Genzyme has been declared effective by the U.S. Securities and Exchange Commission.
A new pharmaceutical candidate enters Lundbeck's development pipeline
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.
Merck and Its Employees to Donate to Japanese Relief Effort
- Details
- Category: Merck Group
Merck KGaA announced that in order to provide assistance to the Japanese people following the earthquake and tsunami that devastated parts of their country, the company will donate a total of 100 million YEN (approximately EUR 875,000).
UK and US governments reach agreement over AstraZeneca tax matters
- Details
- Category: AstraZeneca
AstraZeneca has been informed that the UK and US governments' tax authorities have agreed to the terms of an Advance Pricing Agreement regarding transfer pricing arrangements for AstraZeneca's US business for the 13-year period from 2002 to the end of 2014.
More Pharma News ...
- GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
- Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
- Sanofi-aventis Strengthens Commitment to Ophthalmology through Partnership with The Vision Institute
- SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation
- Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor
- Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint
- Novartis receives European Commission approval for Gilenya®